论文部分内容阅读
目的:观察对慢性阻塞性肺疾病患者应用噻托溴铵药物联合沙美特罗替卡松药物进行治疗所得到的临床疗效,探讨该种治疗方法的安全性。方法:作为研究对象的80例患者,是从该院于2014年10月至2015年10月期间收治的患者中随机抽取出来的,所有患者均被确诊为慢性阻塞性肺疾病,回顾性分析所有患者的临床资料。以治疗方式的不同为主要根据,对这80例患者进行分组,将应用沙美特罗替卡松药物进行治疗的40例患者当作对照组,将应用噻托溴铵药物联合沙美特罗替卡松药物进行治疗的40例患者当作研究组。观察并比较两组患者在临床疗效上的差异。结果:经过药物治疗后,两组患者的呼吸困难评分均得到明显降低;研究组的呼吸困难评分明显低于对照组(P<0.05);研究组的治疗总有效率为92.5%,对照组的治疗总有效率为77.5%,研究组明显高于对照组(P<0.05)。结论:临床上,对慢性阻塞性肺疾病患者应用噻托溴铵药物联合沙美特罗替卡松药物进行治疗,起效快,也可以有效提高治疗总有效率,能够取得较为理想的疗效,不失为一种安全、有效的治疗方法,值得临床推广使用。
Objective: To observe the clinical efficacy of tiotropium in combination with salmeterol and fluticasone in patients with chronic obstructive pulmonary disease (COPD) and explore the safety of this treatment. Methods: Totally 80 patients were selected randomly from the patients admitted from October 2014 to October 2015 in the hospital. All patients were diagnosed as chronic obstructive pulmonary disease. All patients were retrospectively analyzed The patient’s clinical data. The main basis for the different treatment methods, the 80 patients were grouped, the application of salmeterol and fluticasone drugs for treatment of 40 patients as a control group, the application of tiotropium combined with salmeterol Forty patients treated with pine medication served as study groups. Observed and compared the difference between the two groups in clinical efficacy. Results: The scores of dyspnea in both groups were significantly decreased after drug treatment. The scores of dyspnea in the study group were significantly lower than those in the control group (P <0.05). The total effective rate in the study group was 92.5% The total effective rate was 77.5%, which was significantly higher in the study group than in the control group (P <0.05). Conclusions: Clinically, the use of tiotropium in combination with salmeterol and fluticasone in patients with chronic obstructive pulmonary disease has rapid onset of efficacy and can effectively improve the total effective rate of treatment and achieve satisfactory therapeutic effect. A safe and effective treatment, it is worth to promote clinical use.